The development and potential clinical utility of biomarkers for HDAC inhibitors.

Shi BW, Xu WF

Drug Discov Ther. 2013; 7(4):129-136.

DOI: 10.5582/ddt.2013.v7.4.129

Summary Full Text (PDF)

Adjuvant therapy for hepatocellular carcinoma: Current situation and prospect.

Wang ZG, Zhang GF, Wu JC, Jia MK

Drug Discov Ther. 2013; 7(4):137-143.

DOI: 10.5582/ddt.2013.v7.4.137

Summary Full Text (PDF)

Synthesis and biological evaluation of novel anthranilamide derivatives as anticancer agents.

Liu JZ, Liang W, Wang YY, Zhao GS

Drug Discov Ther. 2013; 7(4):144-152.

DOI: 10.5582/ddt.2013.v7.4.144

Summary Full Text (PDF)

Use of silkworms to evaluate the pathogenicity of bacteria attached to cedar pollen.

Hu Y, Hamamoto H, Sekimizu K

Drug Discov Ther. 2013; 7(4):153-157.

DOI: 10.5582/ddt.2013.v7.4.153

Summary Full Text (PDF)

Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment.

Gupta SK, Kantesaria B, Glue P

Drug Discov Ther. 2013; 7(4):158-163.

DOI: 10.5582/ddt.2013.v7.4.158

Summary Full Text (PDF)

Adjuvant systemic drug therapy and recurrence of hepatocellular carcinoma following curative resection.

Zhong YS, Liu B, Deng MH, Xu RY

Drug Discov Ther. 2013; 7(4):164-166.

DOI: 10.5582/ddt.2013.v7.4.164

Summary Full Text (PDF)

Intensive research on the prospective use of complementary and alternative medicine to treat systemic lupus erythematosus.

Jiao B, Gao JJ

Drug Discov Ther. 2013; 7(4):167-171.

DOI: 10.5582/ddt.2013.v7.4.167

Summary Full Text (PDF)